COVID-19 Drug-Screening and Resistance Hub (CRUSH)

CRUSH成立于2020年，目的是解决抗病毒开发领域的一个严重缺口。对新冠肺炎大流行的反应表明，在帮助开发针对高后果病毒的疗法和设备方面，对设施和专门知识的需求很大，但提供的设施和专业知识有限。CVR是英国为数不多的拥有支持此类研究的必要基础设施和病毒学专业知识的机构之一。我们已经开发了能够支持SARS-CoV-2研究的模型，但它们必须在高密封性设施(称为生物安全3级，BSL-3)中处理，并需要专业的分子病毒学专业知识。这类工作可以帮助筛选和确定最终可用于帮助患者的潜在抗病毒药物。CRUSH活动最初集中在SARS-CoV-2上，但现在我们已经调整了我们的模型，以包括其他令人担忧的新兴病毒，例如猴痘。我们希望CRUSH成为英国研究社区的稳定和可持续的资源，以加速任何需要高遏制设施的已知或新的高后果病毒的药物发现。CRUSH和合作伙伴的战略目标是为整个生命科学部门更广泛的合作和创新奠定基础，并为快速应对未来的病毒爆发做好准备。

CRUSH was founded in 2020 to address an acute gap in the landscape of antiviral development. The response to the COVID-19 pandemic demonstrated the high demand and limited provision of facilities and expertise to aid the development of therapeutics and devices targeting high-consequence viruses. The CVR is one of a limited number of UK institutions with the necessary infrastructure and virology expertise to support such studies. We have developed models that can support SARS-CoV-2 research, but they must be handled in high containment facilities (known as biosafety level 3, BSL-3) and require specialised molecular virology expertise. This type of work can help screen and identify potential antiviral drugs that can ultimately be used to help patients. CRUSH activities have initially focused on SARS-CoV-2, but we have now adapted our models to include other emerging viruses of concern, e.g. monkeypox. We want CRUSH to be a stable?and sustainable?resource for the UK’s research communities?to accelerate drug discovery for?any?known or novel?high consequence?virus requiring high containment facilities. A strategic goal of CRUSH and partners is to establish a foundation for broader collaboration and innovation across the Life Sciences sector and to be prepared to rapidly respond to future viral outbreaks.